Abstract |
Allogeneic hematopoietic stem cell transplantation is a successful treatment for hematologic malignancies and a variety of genetic and metabolic disorders. In the period following stem cell transplantation, the immune-compromised milieu allows opportunistic pathogens to thrive. Epstein-Barr virus-associated post-transplant lymphoproliferative disease can be a life-threatening complication for transplanted patients because of suppressed T-cell-mediated immunity. We analyzed possible risk factors associated with post-transplant lymphoproliferative disease in a cohort of over 1,000 patients. The incidence of post-transplant lymphoproliferative disease was 4%. Significant risk factors identified by multivariate analysis were: human leukocyte antigen-mismatch (P<0.001), serological Epstein-Barr virus mismatch recipient-/donor+ (P<0.001), use of reduced intensity conditioning (P=0.002), acute graft-versus-host disease grade II to IV (P=0.006), pre-transplant splenectomy (P=0.008) and infusion of mesenchymal stromal cells (P=0.015). The risk of post-transplant lymphoproliferative disease has increased in more recent years, from less than 2% before 1998 to more than 6% after 2011. Additionally, we show that long-term survival of patients with post-transplant lymphoproliferative disease is poor despite initial successful treatment. The 3-year survival rate among the 40 patients with post-transplant lymphoproliferative disease was 20% as opposed to 62% among patients without post-transplant lymphoproliferative disease (P<0.001). The study identifies patients at risk of post-transplant lymphoproliferative disease after transplantation in need of pre-emptive measures.
|
Authors | Michael Uhlin, Helena Wikell, Mikael Sundin, Ola Blennow, Markus Maeurer, Olle Ringden, Jacek Winiarski, Per Ljungman, Mats Remberger, Jonas Mattsson |
Journal | Haematologica
(Haematologica)
Vol. 99
Issue 2
Pg. 346-52
(Feb 2014)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 24056821
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Allografts
- Epstein-Barr Virus Infections
(etiology, mortality, prevention & control)
- Female
- Follow-Up Studies
- Graft vs Host Disease
(etiology, mortality, prevention & control, virology)
- Hematopoietic Stem Cell Transplantation
- Herpesvirus 4, Human
- Humans
- Lymphoproliferative Disorders
(etiology, metabolism, prevention & control, virology)
- Male
- Retrospective Studies
- Risk Factors
|